Company news
Mabwell (shanghai) Bioscience Co., Ltd. Class A (SSE:688062) news
Mabwell (shanghai) Bioscience Co., Ltd. Class A news releases on 6ix. Latest, Nov 4, 2025: Announcement on Progress in Repurchasing Shares through Call Auction
Press releases — page 2
Announcement on Progress in Repurchasing Shares through Call Auction
November 3, 2025
Report for Q3 2025
October 30, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
October 24, 2025
Announcement on Convening the 2025 Semi-Annual and Q3 Performance Briefing
October 21, 2025
Announcement on the Results of Issuance of the 2025 Phase I Targeted Science and Technology Innovation Bonds
October 16, 2025
Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711 to Be Presented at 2025 ESMO Congress
October 14, 2025
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from NMPA
October 14, 2025
Announcement on Voluntary Disclosure of the Poster Presentation of Data and Latest Progress in 7MW3711 at the 2025 European Society for Medical Oncology (ESMO) Congress
October 13, 2025
Notice on Convening the 2nd Extraordinary General Meeting in 2025
October 8, 2025
Announcement on Voluntary Disclosure of Acceptance of Marketing Authorization Application for 9MW0813 Injection
September 19, 2025
Announcement on Initially Repurchasing Shares Through Call Auction
September 18, 2025
Mabwell Bioscience and Aditum Bio Announce Formation of Kalexo Bio to Advance Innovative siRNA Therapy for Cardiovascular Disorders
September 17, 2025
Mabwell Secures Pakistan's First Denosumab Injection Approval
September 5, 2025
Announcement on Abnormal Fluctuations in Stock Trading
September 2, 2025
Announcement on Voluntary Disclosure of Clinical Trial Applications for 9MW3811 Injection Accepted by China NMPA
August 31, 2025
Special Report on Semi-annual Deposit and Actual Use of Raised Funds in 2025
August 29, 2025
Mabwell's CDH17-targeting ADC 7MW4911 Receives IND Clearance from FDA
August 19, 2025
Announcement on Voluntary Disclosure of FDA Approval for the Clinical Trial Application for 7MW4911 Injection
August 18, 2025
Mabwell Announces First Patient Dosed in the US Clinical Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs
August 12, 2025
Announcement on Adjusting Upper Limit of Shares Repurchase Price
August 5, 2025
Announcement on the Receipt of Decision for Administrative Penalty by Chairman and General Manager
August 4, 2025
Mabwell Announces IND Application Acceptance for CDH17-Targeting ADC 7MW4911 from Both NMPA and FDA
August 1, 2025
Announcement on Voluntary Disclosure of Clinical Trial Applications for 7MW4911 Injection Accepted by China NMPA and U.S. FDA
July 31, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
July 21, 2025
Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders Not Subject to Sales Restrictions Concerning Share Repurchase
July 3, 2025
Announcement on Progress in Introducing Investors
June 30, 2025
Mabwell Announces Novel Drug Technology License Agreement with Qilu Pharmaceutical for Albipagrastim alfa for Injection
June 27, 2025
Notice on Convening the 1st Extraordinary General Meeting in 2025
June 26, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
June 20, 2025
Indicative Announcement on Proposal of Chairman and General Manager to Repurchase the Company's Shares
June 4, 2025
Mabwell Receives NMPA Approval for Albipagrastim alfa for Injection (MAILISHENG)
May 30, 2025
Announcement on Voluntary Disclosure of Marketing Approval of Mailisheng by the National Medical Products Administration
May 29, 2025
Mabwell Announces Clinical Data of Multiple ADCs to be presented at 2025 ASCO Annual Meeting
May 23, 2025
Announcement on Voluntary Disclosure of Multiple Clinical Research Results Selected as Reports for the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
May 22, 2025
Announcement on Reply to the Supervision and Inquiry Letter Regarding Information Disclosure of the 2024 Annual Report
May 20, 2025
Mabwell Releases 6 Study Results of Innovative Drugs and Platforms at the 2025 AACR Annual Meeting
April 30, 2025
Mabwell to Present Clinical Data of 9MW2821 Combined with Toripalimab in Patients with UC in an Oral Presentation at 2025 ASCO
April 24, 2025
Mabwell Announces NMPA Approval to Initiate Clinical Trial of novel B7-H3-targeting ADC for Advanced Solid Tumors in Combination with PD-1 Inhibitor
April 2, 2025
Mabwell to Present results of 6 studies at the 2025 American Association for Cancer Research (AACR) Annual Meeting
March 26, 2025